

RHINOMED RECEIVES REGULATORY CLEARANCE FOR TAIWAN

July 6th 2017. Melbourne, Australia.

Australian medical technology company Rhinomed Ltd (ASX:RNO) is pleased to announce it has successfully registered Mute and Turbine with the Taiwanese Food and Drug Administration (TFDA) for distribution and sale of its Turbine and Mute products as Class I medical devices in the Taiwanese market.

This regulatory clearance enables Rhinomed to import and sell both products into Taiwan under this medical classification and importantly, continue early dialogue with distributors seeking to distribute Mute in Taiwan.

The license extends through to June 22, 2022.

Media Enquiries

Michael Johnson, CEO & Director
+61 (03) 8416 0900
mjohnson@rhinomed.global

Follow us on **Twitter** @rhinomedceo @mutesnoring @theturbinecom

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global